Structure (Beae9b9a D630 463b Ae93 F3da73c7049e 01)
Duloxetine Capsule, Delayed Release
Product Images NDC 50090-6775
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 50090-6775). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Beae9b9a D630 463b Ae93 F3da73c7049e 02)
This text provides data on the proportion of patients with relapse in a treatment study. The treatment options mentioned are "Placebo" and "DULOXETINE". The numbers 08, 04, 02, and 00 may represent the percentage of patients with relapse for each treatment group. The chart shows a time axis ranging from 0 to 150 days, indicating the time from randomization to relapse. The method used to estimate the relapse rate is the Kaplan-Meier estimator. The texts also mention numbers 50, 100, 150, and 20, but their meaning is unclear without additional context.*
Figure 2 (Beae9b9a D630 463b Ae93 F3da73c7049e 03)
The text provided is a table showing the proportion of patients with relapse for a specific treatment (Placebo - DULOXETINE) at different time intervals (in days) from randomization. The table includes values for the proportion of relapsed patients for each time interval.*
Figure 1 (Beae9b9a D630 463b Ae93 F3da73c7049e 04)
Figure 2 (Beae9b9a D630 463b Ae93 F3da73c7049e 05)
Fig 5 (Beae9b9a D630 463b Ae93 F3da73c7049e 06)
Fig 6 (Beae9b9a D630 463b Ae93 F3da73c7049e 07)
Fig 7 (Beae9b9a D630 463b Ae93 F3da73c7049e 08)
Figure 7 shows the percentage of pediatric patients aged 13 to 17 years old with Juvenile Fibromyalgia Syndrome achieving various levels of pain relief after 12 weeks of treatment. The study (FM-4) evaluated the efficacy of Duloxetine 60mg once daily compared to a placebo. The graph displays the percentage of patients who experienced improvement in pain levels, ranging from 0 to 100 percent. The pain relief was measured using the Brief Pain Inventory - Modified short Form: Adolescent Version Average Pain Score. Patients in the Duloxetine group received 30 mg once daily for the first week and then were titrated to 60 mg once daily for the remaining 12 weeks, based on tolerability.*
Figure 8 (Beae9b9a D630 463b Ae93 F3da73c7049e 09)
Figure 9 (Beae9b9a D630 463b Ae93 F3da73c7049e 10)
Percentage of Patients Improved:
This text provides information on the percentage of patients who experienced improvement in their condition. Unfortunately, there are some characters missing or unreadable, making it difficult to determine the full context of the information.*
Figure 10 (Beae9b9a D630 463b Ae93 F3da73c7049e 11)
Percentage of Patients Improved:
This text provides information about the percentage of patients who experienced improvement in a specific condition. However, the rest of the information is not readable and cannot be used to generate a useful description.*
Label Image (Lbl500906775)
This is a product description for a medication called "BOLoXETINE Delayed-Release 60 mg". It is a capsule that comes in a pack of 30. The text also mentions the storage temperature of 77 degrees Celsius.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
